natgillin/translations-raw huggingface dataset:
After oral administration to cats, ibafloxacin is rapidly absorbed with maximal plasma levels observed at 1 hour when administered without food and 2 hours when administered with food.
Ibafloksacin se po peroralnem dajanju pri mačkah hitro absorbira in doseže največjo raven v plazmi v 1 uri, kadar ga dajemo brez hrane, in v 2 urah, kadar ga dajemo s hrano.
After oral administration, avanafil is excreted as metabolites predominantly in the faeces (approximately 63% of administered oral dose) and to a lesser extent in the urine (approximately 21% of the administered oral dose).
Po peroralni uporabi se avanafil v obliki presnovka pretežno izloči z blatom (približno 63 % peroralnega odmerka) ter v manjšem obsegu z urinom (približno 21 % peroralnega odmerka).
After oral administration, desloratadine selectively blocks peripheral histamine H1- receptors because the substance is excluded from entry to the central nervous system.
Po peroralni uporabi selektivno zavira le periferne receptorje H1, saj učinkovina ne prehaja v osrednji živčni sistem.
After oral administration, desloratadine selectively blocks peripheral histamine H1-receptors because the substance is excluded from entry to the central nervous system.
Po peroralni uporabi selektivno blokira periferne receptorje H1, ker učinkovina ne prehaja v osrednje živčevje.
After oral administration, pyriproxyfen is rapidly metabolized, principally by hydroxylation, and eliminated mainly in the faeces, and to a lesser extent in the urine.
Po peroralni uporabi se piriproksifen hitro presnovi, predvsem s hidroksilacijo in v glavnem izloča z blatom in v manjši meri z urinom.
After oral administration, telmisartan is almost exclusively excreted with faeces mainly as unchanged compound.
Po peroralni uporabi se telmisartan izloči skoraj izključno v blatu, pretežno kot nespremenjena spojina.
After oral administration, the Cmax of rivastigmine was approximately 60% higher and the AUC of rivastigmine was more than twice as high in subjects with mild to moderate hepatic impairment than in healthy subjects.
Po peroralnem odmerjanju je bila Cmax rivastigmina za približno 60% večja in AUC rivastigmina več kot dvakrat večja pri osebah z blago do zmerno jetrno okvaro kot pri zdravih osebah.
After oral administration, the maximum plasma concentration of rilpivirine is generally achieved within 4 to 5 hours.
Po peroralnem dajanju so največje koncentracije rilpivirina v plazmi običajno dosežene v roku 4–5 ur.
After oral administration, the systemic exposure is proportional to dose up to 500 mg.
Po peroralnem dajanju je sistemska izpostavljenost sorazmerna danemu odmerku do 500 mg.
After oral and intravenous administration of radiolabeled lacosamide, approximately 95% of radioactivity administered was recovered in the urine and less than 0.5% in the feces.
Po peroralni in intravenski aplikaciji radioaktivno označenega lakozamida so približno 95 % radioaktivnosti zaznali v seču in manj kot 0,5 % v blatu.
After oral application in the rat, emodepside is distributed to all organs.
Pri podganah se po peroralnem dajanju, emodepsid porazdeli po vseh organih.
After oral doses of 80 mg three times a day a more than dose proportional increase in sildenafil plasma levels has been observed.
Po peroralnih odmerkih 80 mg trikrat na dan so opažali povečanje koncentracije sildenafila v plazmi, ki je bilo več kot odmerku sorazmerno.
After oral dosing of vardenafil AUC and Cmax increase almost dose proportionally over the recommended dose range (5 – 20 mg).
Vrednosti AUC in Cmax se po peroralni uporabi priporočenih odmerkov vardenafila (5 do 20 mg) večata skoraj sorazmerno z odmerkom.
After oral dosing of vardenafil AUC and Cmax increase almost dose proportionally over the recommended dose range (5-20 mg).
Vrednosti AUC in Cmax se po peroralni uporabi priporočenih odmerkov vardenafila (5 do 20 mg) večata skoraj sorazmerno z odmerkom.
After oral ingestion the labelled urea reaches the gastric mucosa.
Označena sečnina se po zaužitju razširi v želodčno sluznico.
After oral three times a day dosing of sildenafil, AUC and Cmax increase in proportion with dose over the dose range of 20-40 mg.
Po peroralni uporabi sildenafila trikrat na dan se AUC in Cmax v priporočenem razponu odmerkov (od 20 do 40 mg) večata sorazmerno z odmerkom.
After Placement
Po implantaciji
After preparation each ml contains 10 mg of infliximab
Po pripravi en ml vsebuje 10 mg infliksimaba.
After preparation, 0.2 mL of suspension contains 2 mg somatropin (10 mg/mL).
Po rekonstituciji 0,2 ml suspenzije vsebuje 2 mg somatropina (10 mg/ml).
After preparation, the intravenous infusion solution can be used at room temperature (15 to 30ºC) for a period up to 14 hours.
Po končni pripravi lahko raztopino za intravensko infuzijo uporabite pri sobni temperaturi (med 15 in 30 ºC) v obdobju do 14 ur.
After preparation, the intravenous infusion solution can be used at room temperature (15ºC - 30ºC) for a period up to 14 hours.
Po končni pripravi lahko raztopino za intravensko infuzijo pri sobni temperaturi (15 ºC – 30 ºC) uporabimo v obdobju do 14 ur.
After preparation, the intravenous infusion solution can be used at room temperature (15ºC-30ºC) for a period up to 14 hours.
Po končni pripravi lahko raztopino za intravensko infuzijo pri sobni temperaturi (15 ºC – 30 ºC) uporabimo v obdobju do 14 ur.
After preparation, the suspension should be administered immediately.
Suspenzijo je treba zaužiti takoj po pripravi.
After preparation, the suspension should be taken immediately.
Suspenzijo je treba zaužiti takoj po pripravi.
After preparing the Enbrel solution, immediate use is recommended.
Po pripravi naj se raztopina zdravila Enbrel po možnosti uporabi takoj.
After primary vaccination the rate of subjects with neutralising antibody titres > 20, seroconversion rate and seroconversion factor as measured by microneutralisation assay (MN) in adults aged 18 to 59 years and in older people aged 60 years and above were as follows:
Odstotek oseb, ki imajo titer nevtralizirajočih protiteles večji od 20, ter odstotek serokonverzije in faktor serokonverzije, izmerjeni s testom mikronevtralizacije (MN) po prvem cepljenju odraslih, starih od 18 do 59 let, in starejših oseb, starih 60 let ali več, so bili naslednji:
After primary vaccination the rate of subjects with neutralising antibody titres ≥ 20, seroconversion rate and seroconversion factor as measured by microneutralisation assay (MN) in adults aged 18 to 59 years and in older subjects aged 60 years and above were as follows:
Odstotek oseb, ki imajo titer nevtralizirajočih protiteles večji od 20, ter odstotek serokonverzije in faktor serokonverzije, izmerjeni s testom mikronevtralizacije (MN) po prvem cepljenju odraslih, starih od 18 do 59 let, in starejših oseb, starih 60 let ali več, so bili naslednji:
After proper training in injection technique, patients may self-inject using the pre-filled syringe if their physician determines that it is appropriate and with medical follow-up as necessary.
Z uporabo napolnjene brizge si lahko bolniki zdravilo injicirajo sami, če so bili za to ustrezno usposobljeni ter če zdravnik meni, da je to primerno in bolnikovo zdravljenje po potrebi spremlja.
After proper training in injection technique, patients may self-inject with RoActemra if their physician determines that it is appropriate.
Po primernem usposabljanju o tehniki injiciranja si lahko bolniki sami injicirajo zdravilo RoActemra, če zdravnik meni, da je to primerno.
After proper training in subcutaneous injection technique, patients may self-inject with Simponi if their physician determines that this is appropriate, with medical follow-up as necessary.
Po ustreznem usposabljanju iz tehnike subkutanega injiciranja, si lahko bolniki sami injicirajo zdravilo Simponi, če njihov zdravnik odloči, da je to primerno, po potrebi tudi pod zdravniškim nadzorom.
After proper training in the correct injection technique, patients or their caregivers may inject Ilaris if the physician determines that it is appropriate and with medical follow-up as necessary (see section 6.6).
Bolniki ali njihovi skrbniki smejo sami injicirati zdravilo Ilaris, če so se naučili pravilne tehnike injiciranja in če zdravik presodi, da je to za njih primerno, in kasneje na ustrezen način preveri, če tako zdravljenje pri bolnikih pravilno poteka (glejte poglavje 6.6).
After proper training, the injection can be given by yourself or given by another person, for example, a family member or friend.
Po ustreznem urjenju si lahko injekcije dajete sami ali vam jih daje kdo drug, na primer svojec ali prijatelj.
After Purevax RC has been made up, 1 ml is injected under the skin.
Ko zdravilo Purevax RC pripravimo, ga 1 ml injiciramo pod kožo.
After Purevax RCP FeLV has been made up, 1 ml is injected under the skin.
Ko zdravilo Purevax RCP FeLV pripravimo, ga 1 ml injiciramo pod kožo.
After Purevax RCP has been made up, 1 ml is injected under the skin.
Ko zdravilo Purevax RCP pripravimo, ga 1 ml injiciramo pod kožo.
After Purevax RCPCh FeLV has been made up, 1 ml is injected under the skin.
Ko zdravilo Purevax RCPCh FeLV pripravimo, ga 1 ml injiciramo pod kožo.
After Purevax RCPCh has been made up, 1 ml is injected under the skin.
Ko zdravilo Purevax RCPCh pripravimo, ga 1 ml injiciramo pod kožo.
After radiolabelling
Po radiooznačevanju
After radiolabelling the antibody and diluting a 10 µl sample with 1.5 ml saline, immediately determine the radiochemical purity by Instant Thin Layer Chromatography on silica gel impregnated glass fiber strips, 1 × 9 cm using acetone as the solvent.
Po radioaktivni označitvi protitelesa in spiranju 10µl vzorca z 1,5 ml 0,9% raztopine natriejvega klorida za injiciranje takoj določite radiokemijsko čistoto s tenkoplastno kromatografijo hitre izvedbe (ITLC – Instant Thin Layer Chromatography) na s silikagelom impregniranih ploščicah iz steklenih vlaken, 1 x 9 cm, topilo je aceton.
After radiolabelling with sodium pertechnetate ( Tc) solution, the technetium ( Tc) besilesomab solution obtained is indicated in adults for scintigraphic imaging, in conjunction with other appropriate imaging modalities, for determining the location of inflammation/infection in peripheral bone in adults with suspected osteomyelitis.
Po radioaktivnem označevanju z raztopino natrijevega (99mTc) pertehnetata je dobljena raztopina tehnecijevega (99mTc) besilesomaba indicirana pri odraslih bolnikih za scintigrafsko slikanje skupaj z drugimi primernimi načini slikanja za določanje mesta vnetja/okužbe v perifernih kosteh pri odraslih s sumom na osteomielitis.
After radiolabelling, an immediate use is recommended.
Po označevanju z radioizotopom je priporočljiva takojšnja uporaba.
After radiolabelling, an immediate use is recommended.
Po označevanju z radioizotopom se priporoča takojšnja uporaba.
After radiolabelling, immediate use is recommended.
Po označevanju z radioizotopom je priporočljiva takojšnja uporaba.
After randomized withdrawal from therapy at Week 32, approximately 70% of patients in Study ESTEEM 1, and 65.6% of patients in Study ESTEEM 2, regained PASI-75 (ESTEEM 1) or PASI-50 (ESTEEM 2) responses after re-initiation of apremilast treatment.
Po randomizirani odtegnitvi terapije v 32. tednu je približno 70 % bolnikov v študiji ESTEEM 1 in 65,6 % bolnikov v študiji ESTEEM 2 po ponovni uvedbi zdravljenja z apremilastom spet pridobilo odziv PASI-75 (ESTEEM 1) ali PASI-50 (ESTEEM 2).
After reaching peak concentration, plasma disposition of telbivudine declined in an bi-exponential manner with a terminal elimination half-life (t1/2) of 41.8 ± 11.8 hours.
Po doseženi najvišji koncentraciji je upadala razpoložljivost telbivudina v plazmi bieksponentno s končnim razpolovnim časom izločanja (t1/2) 41,8 ± 11,8 ur.
After receiving Flebogamma DIF, the results of certain blood tests (serological tests) may be interfered for a certain time.
Po uporabi zdravila Flebogamma DIF so lahko rezultati nekaterih krvnih preiskav (seroloških testov) nekaj časa moteni.
After reconsititution use within 3 hours.
Po rekonstituciji uporabite v roku 3 ur.
After reconst. immediate use recommended.
Zdravilo je priporočljivo uporabiti takoj po rekonstituciji.
After reconstitution
Po pripravi:
After reconstitution
Po raztapljanju praška
After reconstitution (addition of 5 ml water for injections to the vial to dissolve the powder), 1 ml contains 50 mg bivalirudin.
Po rekonstituciji (za raztopitev praška se v vialo doda 5 ml vode za injekcije) 1 ml vsebuje 50 mg bivalirudina.
After reconstitution (see section 6.6), each vial contains 25 mg/ml of pemetrexed.
Po rekonstitiuciji vsebuje (glejte poglavje 6.6) ena viala 25 mg/ml pemetrekseda.
After reconstitution (see section 6.6), each vial contains 25 mg/mL of pemetrexed.
Po rekonstituciji ena viala vsebuje 25 mg/ml pemetrekseda.
After reconstitution (see section 6.6), each vial contains 25 mg/ml of pemetrexed.
Po rekonstituciji vsebuje ena viala 25 mg/ml pemetrekseda.
After reconstitution 1 ml concentrate contains 1 mg topotecan.
Po pripravi vsebuje 1 ml koncentrata 1 mg topotekana.
After reconstitution 1 ml contains 10 mg of sildenafil (as citrate).
Po rekonstituciji 1 ml vsebuje 10 mg sildenafila v obliki sildenafilijevega citrata.
After reconstitution 1 ml of the reconstituted solution contains 20 mg degarelix.
Po rekonstituciji vsebuje 1 ml rekonstituirane raztopine 20 mg degareliksa.
After reconstitution 1 ml of the reconstituted solution contains 40 mg degarelix.
Po rekonstituciji vsebuje 1 ml rekonstituirane raztopine 40 mg degareliksa.
After reconstitution and dilution
Po pripravi in redčenju
After reconstitution and dilution 1 ml of solution contains 1 mg fosaprepitant (1 mg/ml).
Po pripravi in redčenju 1 ml raztopine vsebuje 1 mg fosaprepitanta (1 mg/ml).
After reconstitution and dilution of the solution for intravenous infusion, this medicine contains between 0.6-6 mmol sodium per dose depending on the infusion fluid for dilution.
Po rekonstituciji in razredčitvi raztopine za intravensko infundiranje to zdravilo vsebuje 0,6-6 mmol natrija na odmerek, odvisno od infuzijske tekočine za razredčenje.
After reconstitution and dilution of the solution for intravenous infusion, this medicine contains between 1-10 mmol potassium per dose depending on the infusion fluid for dilution.
Po rekonstituciji in razredčitvi raztopine za intravensko infundiranje to zdravilo vsebuje 1-10 mmol kalija na odmerek, odvisno od infuzijske tekočine za razredčenje.
After reconstitution and dilution, the preparation is administered by intravenous infusion.
Po rekonstituciji in razredčitvi (se pripravek aplicira z intravenskim infundiranjem.
After reconstitution and dilution, the solution should be administered by intravenous infusion over approximately 1 hour.
Po pripravi koncentrata in redčenju je treba raztopino intravensko infundirati v približno eni uri.
After reconstitution and infusion:
Rekonstituirane raztopine in raztopine za infundiranje:
After reconstitution each mL contains 10 mg infliximab.
Po rekonstituciji en ml vsebuje 10 mg infliksimaba.
After reconstitution each mL contains 10 mg infliximab.
Po rekonstituciji vsebuje vsak ml 10 mg infliksimaba.
After reconstitution each mL contains 10 mg of infliximab.
Po rekonstituciji vsebuje en mililiter 10 mg infliksimaba.
After reconstitution each ml contains 10 mg of micafungin (as sodium).
Po pripravi raztopine vsebuje 1 ml raztopine 10 mg mikafungina (v obliki natrijeve soli).
After reconstitution each ml contains 10 mg of voriconazole.
Po rekonstituciji 1 mililiter vsebuje 10 mg vorikonazola.
After reconstitution each ml contains 15 mg of telavancin.
Po rekonstituciji en ml vsebuje 15 mg telavancina.
After reconstitution each ml contains 2,500 units of asparaginase.
Po rekonstituciji en mililiter vsebuje 2.500 enot asparaginaze.
After reconstitution each ml contains 20 mg dalbavancin.
Po rekonstituciji en ml vsebuje 20 mg dalbavancina.
After reconstitution each ml contains 20 mg of micafungin (as sodium).
Po pripravi raztopine vsebuje 1 ml raztopine 20 mg mikafungina (v obliki natrijeve soli).
After reconstitution each ml contains 50 mg tedizolid phosphate.
Po rekonstituciji en ml vsebuje 50 mg tedizolid fosfata.
After reconstitution each ml contains 60 mg of vedolizumab.
Po rekonstituciji en ml vsebuje 60 mg vedolizumaba.
After reconstitution each ml of the solution contains 20 mg degarelix.
Po rekonstituciji vsebuje en ml raztopine 20 mg degareliksa.
After reconstitution each ml of the solution contains 40 mg degarelix.
Po rekonstituciji vsebuje en ml raztopine 40 mg degareliksa.
After reconstitution each ml of the solution contains 5 mg olanzapine
Po pripravi vsak ml raztopine vsebuje 5 mg olanzapina.
After reconstitution each ml of the solution contains 5 mg olanzapine.
Po pripravi vsak ml raztopine za injiciranje vsebuje 5 mg olanzapina.
After reconstitution each ml of the suspension contains 10 mg of sildenafil (as citrate).
Po rekonstituciji 1 ml suspenzije vsebuje 10 mg sildenafila v obliki sildenafilijevega citrata.
After reconstitution each vial contains 25 mg/ml of pemetrexed.
Po pripravi ena viala vsebuje 25 mg/ml pemetrekseda.
After reconstitution immediate use recommended.
Zdravilo je priporočljivo uporabiti takoj po pripravi.
After reconstitution it is recommended to promptly dilute the vials (see below).
Po rekonstituciji je priporočljivo takoj razredčiti vsebino viale (glejte spodaj).
After reconstitution one vial contains 125 mg/ml of omalizumab (150 mg in 1.2 ml).
Po rekonstituciji viala vsebuje 125 mg/ml omalizumaba (150 mg v 1,2 ml).
After reconstitution one vial contains 125 mg/ml of omalizumab (75 mg in 0.6 ml).
Po rekonstituciji viala vsebuje 125 mg/ml omalizumaba (75 mg v 0,6 ml).
After reconstitution one vial contains 15 mg** desirudin* per 0.5 ml
Po rekonstituciji ena viala vsebuje 15 mg** desirudina* na 0,5 ml.
After reconstitution the chemical and physical in-use stability has been demonstrated for 8 hours at 2-25 °C).
Po rekonstituciji so kemijsko in fizikalno obstojnost med uporabo dokazali za 8 ur pri temperaturi
After reconstitution the finished product must be further diluted in 0.9% (w/v) sodium chloride solution for injection, or 5% (w/v) glucose solution for injection to a final volume of 40 ml to 120 ml per 50 mg reconstituted Myocet so that a final concentration of 0.4 mg/ml to 1.2 mg/ml doxorubicin is obtained.
Po rekonstituciji morate končni izdelek dodatno razredčiti v natrijevem kloridu 9 mg/ml (0,9 %) raztopini za injiciranje ali v glukozi 50 mg/ml raztopini za injiciranje na končno prostornino 40 ml do 120 ml na 50 mg rekonstituiranega zdravila Myocet, tako da dobite končno koncentracijo 0,4 mg/ml do 1,2 mg/ml doksorubicina.
After reconstitution the product is stable for 8 hours when stored at 2°C -8°C.
Po rekonstituciji je zdravilo stabilno 8 ur, če je shranjeno pri temperaturi 2 °C–8 °C.
After reconstitution the solution contains 20 mg siltuximab per mL.
Po rekonstituciji razopina vsebuje 20 mg siltuksimaba/ml.
After reconstitution the solution contains 20 mg siltuximab per mL.
Po rekonstituciji vsebuje raztopina 20 mg siltuksimaba na mililiter.
After reconstitution the solution is colourless to slightly yellowish and clear to slightly opalescent and essentially free from visible particles.
Po rekonstituciji je raztopina brezbarvna do rahlo rumenkasta in bistra do rahlo opalescentna ter praktično ne vsebuje vidnih delcev.
After reconstitution this medicinal product contains 0.31 mmol sodium (7 mg) per ml of reconstituted solution.
To zdravilo po pripravi vsebuje 0,31 mmol (7 mg) natrija na mililiter pripravljene raztopine.
After reconstitution this medicinal product contains 0.83 mmol (19 mg) sodium per vial.
To zdravilo po rekonstituciji vsebuje 0,83 mmol (19 mg) natrija na vialo.
After reconstitution TruScient contains 0.2 mg/ml of dibotermin alfa (rhBMP-2)
Po rekonstituciji TruScient vsebuje 0,2 mg/ml dibotermina alfa (rhBMP-2).
After reconstitution use within 4 hours.
Po rekonstituciji porabite v 4 urah.
After reconstitution with 1 ml of solvent, 1 ml of the solution contains 10 mg pegvisomant.
Po pripravi z 1 ml vehikla vsebuje 1 ml raztopine 10 mg pegvisomanta.
After reconstitution with 1 ml of solvent, 1 ml of the solution contains 15 mg pegvisomant.
Po pripravi z 1 ml vehikla vsebuje 1 ml raztopine 15 mg pegvisomanta.
After reconstitution with 1 ml of solvent, 1 ml of the solution contains 20 mg pegvisomant.
Po pripravi z 1 ml vehikla vsebuje 1 ml raztopine 20 mg pegvisomanta.
After reconstitution with 1 ml of solvent, 1 ml of the solution contains 25 mg pegvisomant.
Po pripravi z 1 ml vehikla vsebuje 1 ml raztopine 25 mg pegvisomanta.
After reconstitution with 1 ml of solvent, 1 ml of the solution contains 30 mg pegvisomant.
Po pripravi z 1 ml vehikla vsebuje 1 ml raztopine 30 mg pegvisomanta.
After reconstitution with 10 ml of Water for Injection each ml contains 2 mg of Drotrecogin alfa (activated).
Po pripravi z 10 ml vode za injekcije vsak ml vsebuje 2 mg drotrekogina alfa (aktiviranega).
After reconstitution with 14 ml water for injections, the solution contains 150 U conestat alfa per ml.
Po rekonstituciji s 14 ml vode za injekcije vsebuje raztopina 150 e. konestata alfa na ml.
After reconstitution with 19 ml of water for injections or sodium chloride 9 mg/ml (0.9%) solution for injection a clear solution is obtained.
Po rekonstituciji z 19 ml vode za injekcije ali 9 mg/ml (0.9%) raztopine natrijevega klorida za infundiranje dobite bistro raztopino.
After reconstitution with 2 ml of solvent, the concentration of parecoxib is 20 mg/ml.
Po pripravi z 2 ml vehikla znaša koncentracija parekoksiba 20 mg/ml.
After reconstitution with 2.5 ml of Water for Injection each ml contains 2 mg of Drotrecogin alfa (activated).
Po pripravi z 2,5 ml vode za injekcije vsak ml vsebuje 2 mg drotrekogina alfa (aktiviranega).
After reconstitution with 20 ml solvent, the solution contains approximately 50 mg/ml of human alpha1-proteinase inhibitor.
Po rekonstituciji z 20 ml vehikla vsebuje raztopina približno 50 mg/ml humanega zaviralca alfa1- proteinaze.
After reconstitution with 25 ml Savene diluent, 1 ml of concentrate contains 20 mg dexrazoxane
Po pripravi s 25 ml vehikla Savene, 1 ml koncentrata vsebuje 20 mg deksrazoksana.
After reconstitution with 52 ml of water, the usable volume of oral suspension allows for the retrieval of a total of 10 doses of 75 mg oseltamivir.
Po rekonstituciji z 52 ml vode je uporaben volumen peroralne suspenzije za 10 odmerkov po 75 mg oseltamivirja.
After reconstitution with acceptable solvents, Dynastat may only be injected IV or IM, or into IV
Po pripravi z dovoljenim vehiklom smemo zdravilo Dynastat injicirati samo intravensko ali intramuskularno, ali v intravensko pot, po kateri teče:
After reconstitution with acceptable solvents, Dynastat may only be injected IV or IM, or into IV lines delivering the following:
Po pripravi z dovoljenim vehiklom se sme zdravilo Dynastat injicirati samo intravensko ali intramuskularno, oziroma v intravensko pot, po kateri teče:
After reconstitution with acceptable solvents, Dynastat may only be injected IV or IM, or into IV lines delivering the following:
Po pripravi z dovoljenim vehiklom smemo zdravilo Dynastat injicirati samo intravensko ali intramuskularno, ali v intravensko pot, po kateri teče:
After reconstitution with sodium pertechnetate (99mTc) solution for injection, 99mTc-depreotide is formed.
Po rekonstituciji z raztopino natrijevega pertehnetata(99mTc) za injiciranje, nastane
After reconstitution with sterile water for injection the reconstituted solution is physically and chemically stable for 48 hours at 2°C – 8°C. Any remaining reconstituted solution should be discarded.
Po rekonstituciji s sterilno vodo za injekcije je pripravljena raztopina fizikalno in kemično stabilna 48 ur pri temperaturi od 2 °C–8 °C. Raztopino, ki ostane, je treba zavreči.
After reconstitution with the solvent provided 1 ml of reconstituted solution contains 90 mg enfuvirtide.
Po pripravi s priloženim vehiklom 1 ml pripravljene raztopine vsebuje 90 mg enfuvirtida.
After reconstitution with the solvent provided the medicine may be stored in the refrigerator (2°C - 8°C) for a maximum of 21 days.
Po rekonstituciji s priloženim vehiklom lahko zdravilo shranjujete v hladilniku (2 °C - 8 °C) največ 21 dni.